GRA (REMD-477) for Type 1 Diabetes

"For this medical trial, 30 individuals with diabetes and autoimmune illnesses aged 18 to 65 are being accepted. To qualify for the study applicants must meet a number of criteria, such as having been on an insulin regimen for at least 8 weeks prior to screening, using birth control if applicable, meeting the age range requirement of 18-65 years old, and weighing in at 50 kg or more."

"The qualifications for this trial necessitate that potential participants are between the age of 18 to 65. There is a total of 156 studies conducted with patients younger than 18 and another 179 concerning individuals who exceed the upper limit of 65 years old."

"Affirmative. The information hosted on clinicaltrials.gov reveals that this trial, originally advertised on July 31st 2021, is actively searching for participants. 30 individuals need to be sourced from a single medical facility."

"REMD-477 is rated a 2 on the safety scale due to its current status as a Phase 2 trial, with evidence indicating some protection from harm but none that suggests efficacy."

"Affirmative. The clinicaltrials.gov page for this trial suggests that it is currently recruiting patients, with the original post being from July 31st 2021 and a recent update occurring on November 9th 2022. A total of 30 participants are required to be enrolled at 1 location."

"Presently, 2 clinical trials are being performed to investigate REMD-477; both of these experiments have not yet entered Phase 3. While the majority of studies occur in San Antonio, Texas, there are also two other locations conducting research on this potential remedy."

"The development of REMD-477 began in 2021 and the initial clinical trial was funded by REMD Biotherapeutics, Inc.. Following a successful 30 person Phase 1 assessment, this drug received approval for its second stage of testing. Now two separate trials are ongoing across two cities within one nation."